



AbGenomics International Inc.

## **AbGn-168 Phase I Trial Initiate**

Palo Alto, California--AbGenomics International Inc., a biotechnology company focused on discovering and developing antibody therapeutics, announced today that a development milestone has been achieved with the initiation of a “first in human” Phase I trial of AbGn-168. AbGn-168 is an immunomodulating investigational therapeutic antibody targeting treatment of autoimmune diseases. AbGenomics is eligible to receive a milestone payment from its collaborator Boehringer Ingelheim for this achievement.

AbGn-168 is exclusively licensed to Boehringer Ingelheim. Boehringer Ingelheim is solely responsible for further development and commercialization of AbGn-168 and AbGenomics is eligible to receive development milestone payments and royalties on any sales of AbGn-168.

### **About AbGenomics**

AbGenomics is a global and virtually integrated biopharmaceutical company focused on the discovery and development of novel medicines to treat diseases with unmet medical need and significant market potential. Headquartered in Palo Alto, U.S., AbGenomics has subsidiaries in the Netherlands and in Taiwan. The Company’s strategy is to commercialize its novel products in collaboration with major pharmaceutical partners in order to maximize the opportunity for development and marketing of the Company’s compounds with reduced risk.